Trial Profile
An Open-Label, Single Arm, Multi-Center, Phase 2 Study of PD-1 Antibody SHR-1210 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2022
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary)
- Indications Extranodal NK-T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 16 Jun 2020 Status changed to active, no longer recruiting.
- 08 Dec 2017 New trial record